Cancer-fighting T cells often lose their tumor-killing momentum because they burn through energy too aggressively rather than simply running out of fuel, according to an animal study published in Immunity. Researchers at Memorial Sloan Kettering Cancer Center found that inhibiting the signaling molecule MEK can prevent these immune cells from reaching terminal exhaustion, offering a potential path to make cancer immunotherapy more durable.
Energy Imbalance Drives T Cell Exhaustion
Immunotherapy drugs known as checkpoint inhibitors remove molecular brakes from T cells so they can target tumors more aggressively. Yet these treatments frequently fade over time because the specialized killer cells enter a state of functional depletion known as exhaustion, according to Memorial Sloan Kettering physician-scientist Santosha Vardhana. Patients often experience a brief period of clinical promise before that momentum disappears, Vardhana noted.
The new research demonstrates that exhaustion is not merely a passive loss of function, but rather an energy imbalance. Repeated exposure to tumor antigens places heavy metabolic demands on mitochondria, the cellular structures that convert nutrients into usable energy.
MEK Inhibition Reduces Excessive Energy Demand
To investigate cellular metabolism, the research team analyzed exhausted T cells and discovered a surprising paradox. Even as the cells appeared depleted, they remained highly active metabolically. Lead study author and graduate student Tanmana Mitra explained that these cells were investing enormous resources into protein production rather than running out of energy altogether.
When the investigators exposed the cells to MEK inhibitors, the T cells multiplied more while consuming less energy. Slowing down MEK signaling reduced the frantic production of cytotoxic proteins, allowing a subset of T cells to remain active and capable of self-renewal for longer periods. This mechanism resembles pacing a long endurance drive rather than traveling at maximum speed from the start.
Because the study utilized animal models to uncover how MEK drives exhaustion, researchers are now looking toward human translation. Because Food and Drug Administration-approved MEK inhibitors are already commercially available for other indications, Dr. Vardhana stated that this pacing strategy could potentially be tested in human clinical trials without significant delay to enhance multiple forms of immunotherapy.
>